Osteopore (ASX: OSX) is set to expand its orthopaedic business into Hong Kong after signing a new distribution agreement with local company MontsMed, marking the next step in the company’s planned commercial expansion across the Asia Pacific region.
Osteopore will initially target the orthopaedic trauma reconstruction segment, which the company has identified as the area with the highest likelihood of application for its devices.
The exclusive agreement appoints MontsMed as Osteopore’s Hong Kong distributor for orthopaedic products under a three-year term, with an option to extend for a further year by mutual agreement.
Hong Kong represents a strategically important entry point given its role as a potential gateway to the region and established healthcare infrastructure.
Clinical Demand Scale Highlighted
Data published by local statutory body the Hospital Authority shows there were approximately 106,000 new cases in orthopaedic and traumatology in Hong Kong in 2024, highlighting the scale of clinical demand within the market.
Across the wider region, the Asia Pacific bone graft and substitutes market was estimated at US$662 million in 2024 and is forecast to grow at a compound annual growth rate of 8.2% from 2025 to 2030, with regional growth being driven by increasing rates of orthopaedic disorders and musculoskeletal injuries.
“The expansion of our orthopaedic business into Hong Kong is the latest in a series of planned commercial execution in the region,” chief executive officer Dr Yujing Lim said.
MontsMed chief executive officer Timothy Kong said Osteopore’s products align with the company’s focus on introducing innovative solutions to surgeons and have potential application across orthopaedic trauma reconstruction and tumour cases.
“We look forward to having meaningful conversations with our surgeons about this new and innovative method of bone reconstruction, Mr Kong added.
Track Record in International Markets
Osteopore has introduced its orthopaedic products in Europe, Singapore and Vietnam in recent years, offering custom implants in Europe and both custom and off-the-shelf products in Singapore and Vietnam.
The company said it has seen encouraging adoption from the orthopaedic community across these markets, supporting further international expansion.
The Hong Kong agreement builds on this foundation and extends Osteopore’s commercial footprint in Asia.
Potential benefits from the partnership include regulatory harmonisation initiatives facilitating cross-border use of medical devices, as well as collaborative innovation across the region.
